HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network
Maneno muhimu
Kikemikali
Maelezo
HCV-TARGET is a longitudinal, observational study that will create a carefully maintained research registry of HCV patients treated with antiviral therapies designed to rapidly inform strategies for better management of populations underrepresented in clinical trials, identify and remediate educational gaps relative to treatment guidelines and adverse event management in order to optimize rates of sustained virological response (SVR), and serve as the core resource for important collaborative translational studies utilizing biospecimens and clinical data from diverse patient populations.
HCV-TARGET is a cooperative academic consortium of principal investigators from Clinical and Translational Award (CTSA)-funded academic institutions and community-based sites affiliated with the academic sites in geographic proximity. The Clinical Coordinating Center (CCC) resides at the University of Florida and the Data Coordinating Center (DCC) resides at the University of North Carolina at Chapel Hill.
The HCV-TARGET registry will characterize the population of chronic hepatitis C (HCV) patients who are being treated with antiviral therapies at academic and community sites. Patient characteristics such as age, race, ethnicity, comorbidity, and disease and treatment status will be examined.
HCV-TARGET will also:
1. Provide baseline and treatment response data that will be used to pre-identify candidates for enrollment in future clinical trials. HCV-TARGET will also develop a well-characterized cohort of protease inhibitor treatment failures to be considered for future trials.
2. Establish and maintain data, a specimen bank and other resources for ancillary studies of the pathogenesis, diagnosis, natural history and treatment of HCV infection.
This study will investigate various aspects of treatment response to regimens containing direct-acting antiviral agents for the treatment of chronic hepatitis C, including the following:
- Patients underrepresented in clinical trials of approved antiviral therapies(including African-Americans, patients with cirrhosis, and patients that are considered null responders to treatment.)
- Treatment persistence
- Virological breakthrough
- Impact of viral load measurement on treatment efficacy
- Adverse Event Management and Surveillance.
The secondary aims for this study will investigate the following:
- Sustained virological response (SVR) rates and safety in special populations.
- Surveillance of drug-drug interactions.
- Treatment and management adherence.
- Pretreatment Education in HCV patient population.
- Use of specialty pharmacy for hepatitis C therapy.
Tarehe
| Imethibitishwa Mwisho: | 07/31/2020 |
| Iliyowasilishwa Kwanza: | 11/09/2011 |
| Uandikishaji uliokadiriwa Uliwasilishwa: | 11/14/2011 |
| Iliyotumwa Kwanza: | 11/17/2011 |
| Sasisho la Mwisho Liliwasilishwa: | 08/09/2020 |
| Sasisho la Mwisho Lilichapishwa: | 08/12/2020 |
| Tarehe halisi ya kuanza kwa masomo: | 10/31/2011 |
| Tarehe ya Kukamilisha Msingi iliyokadiriwa: | 11/30/2020 |
| Tarehe ya Kukamilisha Utafiti: | 11/30/2020 |
Hali au ugonjwa
Awamu
Vigezo vya Kustahiki
| Zama zinazostahiki Kujifunza | 18 Years Kwa 18 Years |
| Jinsia Inastahiki Kujifunza | All |
| Njia ya sampuli | Non-Probability Sample |
| Hupokea Wajitolea wa Afya | Ndio |
| Vigezo | Inclusion Criteria: - All adult patients (age 18 or older) being treated with antiviral HCV treatment regimens that contain telaprevir or boceprevir. Exclusion Criteria: - Inability to provide written informed consent. - Currently participating in another clinical trial of hepatitis C therapeutics. Studies comparing HCV RNA assays are not considered exclusionary. |
Matokeo
Hatua za Matokeo ya Msingi
1. Sustained virological response (SVR) [24 months]
Hatua za Matokeo ya Sekondari
1. Treatment persistence [24 months]
2. Virological breakthrough [24 months]
3. Management of adverse events [24 months]
